BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

BioNTech SE (NASDAQ:BNTX) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts. BioNTech SE ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.

TheFly reported on April 10 that Morgan Stanley slightly increased its price target on BNTX from $125 to $126 while ...

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...

Some promising things are happening in health news, including a possible personalized vaccine against pancreatic cancer. Hear ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to ‌start again with a new ...